P53 as a target for anti-cancer immunotherapy

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 • 2,828 citations

The p53 proto-oncogene can act as a suppressor of transformation

1989 • 2,019 citations

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1996 • 1,908 citations

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

1979 • 1,830 citations

Genetic immunization is a simple method for eliciting an immune response

1992 • 1,505 citations

A p16 ^INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma

1995 • 1,147 citations

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1992 • 1,076 citations

Human tumor antigens recognized by T lymphocytes.

1996 • 860 citations

Presence of a Potent Transcription Activating Sequence in the p53 Protein

1990 • 811 citations

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation

1984 • 761 citations

Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

1960 • 736 citations

Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice

1992 • 650 citations

Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene

1990 • 644 citations

TP53 tumor suppressor gene: A model for investigating human mutagenesis

1992 • 584 citations

THE TUMOR SUPPRESSOR GENES

1993 • 509 citations

Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

1982 • 448 citations

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

1995 • 416 citations

Intradermal Immunization of C3H Mice against a Sarcoma That Originated in an Animal of the Same Line

1943 • 363 citations

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.

1985 • 358 citations

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.

1991 • 304 citations

Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.

1992 • 299 citations

Dendritic Cells in Antitumor Immune Responses

1996 • 282 citations

p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.

1992 • 278 citations

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation

1993 • 275 citations

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

1993 • 267 citations

Dendritic Cells in Antitumor Immune Responses

1996 • 219 citations

Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes.

1996 • 201 citations

A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer

1996 • 196 citations

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.

1994 • 168 citations

Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein

1994 • 143 citations

Resistance of polyoma virus immunized mice to transplantation of established polyoma tumors

1961 • 132 citations

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

1996 • 123 citations

Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma.

1992 • 116 citations

Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

1991 • 114 citations

Primary proliferative T cell response to wild‐type p53 protein in patients with breast cancer

1995 • 98 citations

Structural and functional analysis of β2 microglobulin abnormalities in human lung and breast cancer

1996 • 64 citations

Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif.

1994 • 62 citations

Studies on the mechanisms of invasion in cancer. I. Isolation and purification of a factor chemotactic for cancer cells

1970 • 51 citations

IL-12 and Mutant P53 Peptide-Pulsed Dendritic Cells for the Specific Immunotherapy of Cancer

1996 • 39 citations

T Cell-Mediated Cytotoxicity Against p53-Protein Derived Peptides in Bulk and Limiting Dilution Cultures of Healthy Donors

1995 • 31 citations

Molecular analysis of MHC-class-I alterations in human tumor cell lines

1991 • 25 citations

Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes

1996 • 24 citations

MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors.

1992 • 19 citations

Mutant Oncopeptide Immunization Induces CTL Specifically Lysing Tumor Cells Endogenously Expressing the Corresponding Intact Mutant p53

1995 • 16 citations

Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus.

1996 • 15 citations

Cited By (0)

No citing papers found in database